Search results
Moderna’s New Flu-COVID Combi mRNA Vaccine Outperforms Separate Shots In Trials
IFLScience· 4 days agoModerna became a household name thanks to the success of its mRNA vaccine against COVID-19. Along...
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock.
Motley Fool via Yahoo Finance· 7 days agoAnd investing in a safe, high-yielding dividend stock can make the most of your money. That's why a...
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Investing.com· 2 days agoSarepta Therapeutics (NASDAQ:SRPT) stock rose over 3% Thursday after Pfizer (NYSE:PFE) announced...
Pfizer study finds Paxlovid ineffective against Long COVID despite federal research funds
22 WSBT South Bend· 3 days agoLong COVID is a chronic condition resulting from an initial infective with COVID-19, according to...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks· 2 days agoFree Report) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (“DMD”) failed to meet the primary endpoint ...
UPDATE: Pfizer's phase 3 gene therapy trial fails to improve function for boys with Duchenne...
FierceBiotech· 3 days agoPfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 3 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 2 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said ...
Market Today: Boeing Delays 737 Production, Pfizer Extends Losse
Guru Focus· 15 hours agoMarket Performance Overview The S&P 500 and Nasdaq Composite hit fresh record highs this week,...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 2 days agoPharma giant Pfizer Inc. (NYSE: PFE) announced on Wednesday after markets closed that its gene...